Azelaic Acid Patent Expiration
Azelaic Acid is Used for treating inflammatory papules and pustules of mild to moderate rosacea. It was first introduced by Almirall Llc
Azelaic Acid Patents
Given below is the list of patents protecting Azelaic Acid, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Finacea | US9211259 | Antibiotic kit and composition and uses thereof | Feb 28, 2029 | Leo Pharma As |
| Finacea | US9265725 | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof | Dec 08, 2027 | Leo Pharma As |
| Finacea | US10117812 | Foamable composition combining a polar solvent and a hydrophobic carrier | Oct 18, 2027 | Leo Pharma As |
| Finacea | US7700076 | Penetrating pharmaceutical foam | Sep 18, 2027 | Leo Pharma As |
| Finacea | US8435498 | Penetrating pharmaceutical foam |
Mar 01, 2024
(Expired) | Leo Pharma As |
| Finacea | US10322085 | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Oct 24, 2023
(Expired) | Leo Pharma As |
| Finacea | US8722021 | Foamable carriers |
Oct 24, 2023
(Expired) | Leo Pharma As |
| Finacea | US8900554 | Foamable composition and uses thereof |
Oct 24, 2023
(Expired) | Leo Pharma As |
| Finacea | US6730288 | Mousse composition |
Sep 08, 2019
(Expired) | Leo Pharma As |
| Finacea | US6534070 | Composition with azelaic acid |
Nov 18, 2018
(Expired) | Leo Pharma As |
Azelaic Acid's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Azelaic Acid:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation | Virginia Commonwealth University | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1 |